Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Dermatologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches.Dermatol Ther (Heidelb). 2017; 7: 5-19
- Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the us population, 2012.JAMA Dermatol. 2015; 151: 1081-1086
- Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.Am J Prev Med. 2015; 48: 183-187
- NCCN Guidelines Version 2.2022 Breast Cancer.(Available at:)https://www.nccnDate: 2021
- NCCN Guidelines Version 3.2022 Prostate Cancer.(Available at:)https://www.nccn.org/home/Date: 2022
- Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2020; https://doi.org/10.1016/j.jaad.2020.04.088
- Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.Clin Cancer Res. 2015; 21: 175-183
- Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome.Aust N Z J Surg. 1992; 62: 697-701
- The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors.J Surg Oncol. 2012; 106: 811-815
- NCCN Squamous Cell Skin Cancer Guidelines Version 1.2022.(Available at:)https://www.nccn.org/home/member-Date: 2021
- Amin M.B. Edge S.B. Greene F.L. AJCC cancer staging manual. 8th edition. Springer International Publishing, 2017
- Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.JAMA Dermatol. 2013; 149: 402-410
- Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC): a narrative review.Dermatol Ther (Heidelb). 2022; 12: 267-284
- Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.Curr Med Res Opin. 2020; 36: 1301-1307
- Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.Curr Med Res Opin. 2020; 36: 1295-1300
- Invasive squamous cell carcinoma of the skin: defining a high-risk group.Ann Surg Oncol. 2006; 13: 902-909
- Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.J Am Acad Dermatol. 2016; 75: 722-730
- Cutaneous squamous cell carcinoma.Hematol Oncol Clin North Am. 2019; 33: 1-12
- Does sentinel lymph node biopsy have a role in node-positive head and neck squamous carcinoma?.S Afr J Surg. 2013; 51: 22-25
- SLNB in cutaneous SCC: a review of the current state of literature and the direction for the future.J Surg Oncol. 2017; 116: 344-350
- Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.Radiat Oncol. 2016; 11https://doi.org/10.1186/s13014-016-0672-0
- Analysis of gene expression in normal and cancer cells exposed to γ-radiation.J Biomed Biotechnol. 2008; 2008https://doi.org/10.1155/2008/541678
- Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.Br J Cancer. 2011; 104: 488-495
- Genomic analyses identify molecular subtypes of pancreatic cancer.Nature. 2016; 531: 47-52
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.Lancet Oncol. 2020; 21: 294-305
- Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629).J Clin Oncol. 2020; 38: 2916-2925
- Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.BMC Cancer. 2019; 19https://doi.org/10.1186/s12885-019-5808-9
- Incidence of skin cancer in 5356 patients following organ transplantation.Br J Dermatol. 2000; 143: 513-519
- Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? A systematic review and meta-analysis.J Eur Acad Dermatol Venereol. 2019; 33: 828-841
- Differential T-cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals.Exp Dermatol. 2016; 25https://doi.org/10.1111/exd.12878
- The correlation of immune status with ultraviolet radiation–associated mutations in cutaneous squamous cell carcinoma: a case-control study.J Am Acad Dermatol. 2020; 82: 1230-1232
- Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients.PLoS One. 2012; 7https://doi.org/10.1371/journal.pone.0040754
- Melanoma epidemiology, biology and prognosis.EJC Suppl. 2013; 11: 81-91
- Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR.Biochem Biophysical Res Commun. 2003; 306: 1026-1036
- Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study.BMJ (Online). 2017; 357https://doi.org/10.1136/bmj.j2813
- Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.J Am Acad Dermatol. 2017; 76: 114-120.e2
Brouha B., Ferris L., Skelsey M., et al., Genomic atypia to enrich melanoma positivity in biopsied lesions: gene expression and pathology findings from a large US registry study, SKIN J Cutan Med Surg, 5 (1), 2021, 13-18.
- Biopsy use in skin cancer diagnosis: comparing dermatology physicians and advanced practice professionals.JAMA Dermatol. 2015; 151: 899-902
- Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden.SKIN J Cutan Med Surg. 2021; 5: 512-523
Cullison S.R., Jansen B., Yao Z., et al., Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses, SKIN J Cutan Med Surg, 4 (2), 2020, 124-129.
- Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.J Cutan Pathol. 2015; 42: 244-252
- An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.Cancer. 2017; 123: 617-628
- Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA: A Cancer J Clinicians. 2017; 67: 472-492
- Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile–based classification.J Am Acad Dermatol. 2017; 76: 818-825.e3
- Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.Clin Cancer Res. 2007; 13: 806-815
- Molecular classification of cutaneous malignant melanoma by gene expression profiling.Nature. 2000; 406: 536-540
- Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.Cancer Biol Ther. 2005; 4: 1018-1029https://doi.org/10.4161/cbt.4.9.2165
- The gene expression signatures of melanoma progression.Proc Natl Acad Sci U S A. 2005; 102: 6092-6097
- Identification of new genes associated with melanoma.Exp Dermatol. 2011; 20: 502-507
- Altered molecular pathways in melanocytic lesions.Int J Cancer. 2010; 126: 1869-1881
- Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma.Am Surg. 2020; 86: 1561-1564
- Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma.JCO Precis Oncol. 2021; 5: 00119
- Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.J Am Acad Dermatol. 2020; 83: 745-753
- Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.Head and Neck. 2019; 41: 871-879
- Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.Cancer Med. 2019; 8: 2205-2212
- Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.BMC Cancer. 2018; 18https://doi.org/10.1186/s12885-018-4016-3
- Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.J Hematol Oncol. 2017; 10https://doi.org/10.1186/s13045-017-0520-1
- NCCN Clinical Practice Guidelines in Oncology Melanoma: Cutaneous.(Available at:)www.nccn.org/patientsDate: 2022
- Melanoma: cutaneous, version 2.2021 featured updates to the NCCN guidelines.JNCCN J Natl Compr Cancer Netw. 2021; 19: 364-376
- Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.J Am Acad Dermatol. 2019; 80: 149-157.e4
- Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis.JAMA Dermatol. 2020; 156: 953-962
- Factors affecting dermatologists’ use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma.J Drugs Dermatol. 2018; 17: 544-547
- Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients.Curr Med Res Opin. 2016; 32: 1599-1604
- Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging.J Drugs Dermatol. 2018; 17: 196-199
- Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists’ clinical management decisions.J Drugs Dermatol. 2017; 16: 428-431
- Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy.New Engl J Med. 2016; 375: 1845-1855
- Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.Br J Dermatol. 2021; 184: 944-951
- Gene-signature based prediction of relapse-free survival in melanoma patients with known sentinel lymph node status.J Clin Oncol. 2017; 35: e21037
- Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.Eur J Cancer. 2020; 125: 38-45
- Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit.JAMA Dermatol. 2020; 156: 1004-1011
- Guidelines of care for the management of primary cutaneous melanoma.J Am Acad Dermatol. 2019; 80: 208-250
- Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice.Melanoma Management. 2019; 6: MMT32
- The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.Nat Commun. 2018; 9: 3667
- Basal cell carcinoma gene mutations differ between Asian, Hispanic, and Caucasian patients: a pilot study.J Drugs Dermatol. 2021; 20: 504-510
- Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.Future Oncol. 2021; (Published online November 25)https://doi.org/10.2217/fon-2021-1277
- Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.J Eur Acad Dermatol Venereol. 2019; 33: 857-862
- Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test.Dermatol Surg. 2018; 44: 1494-1500
- Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.Eur J Cancer. 2020; 140: 11-18
- A prognostic gene-signature based identification of high-risk thin melanomas.J Clin Oncol. 2018; 36: e21575
- Identifying high-risk tumors within AJCC stage IB–III melanomas using a seven-marker immunohistochemical signature.Cancers (Basel). 2021; 13: 2902
Article info
Publication history
Published online: October 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
